The effects of dose and timing of esomeprazole administration on 24-h, daytime and night-time acid inhibition in healthy volunteers

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 10, 2010, Pages 1249-1256

  Wilder Smith, C ^a   Rohss K ^b   Bokelund Singh, S ^b   Sagar, M ^b   Nagy, P ^b  

^a Brain Gut Research Group   (Switzerland)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EVENING DOSAGE; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; HUMAN; INFLUENZA; LABORATORY TEST; MALE; MORNING DOSAGE; NIGHT; NORMAL HUMAN; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SORE THROAT; STOMACH ACID; TREATMENT DURATION; URTICARIA; VITAL SIGN;

ADMINISTRATION, ORAL; ADULT; ANTI-ULCER AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; HUMANS; MALE; OMEPRAZOLE; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78249247114     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04469.x     Document Type: Article

References (15)

1. Fass R,. Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs 2007; 67: 1521-30.
2. Kahrilas PJ, Shaheen NJ, Vaezi MF,. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1392-413.
3. Hammer J, Schmidt B,. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharmacol Ther 2004; 19: 1105-10.
4. Katz PO, Castell DO, Chen Y, Andersson T, Sostek MB,. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther 2004; 20: 399-406.
5. Wilder-Smith CH, Gennoni MA, Triller J, Scheurer U, Merki HS,. Is a fluoroscopic verification of the electrode position necessary in ambulatory intragastric pH monitoring? Digestion 1992; 52: 1-5.
6. Prichard PJ, Yeomans ND, Mihaly GW, et al. Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology 1985; 88: 64-9.
7. Hendel J, Hendel L, Aggestrup S,. Morning or evening dosage of omeprazole for gastro-oesophageal reflux disease? Aliment Pharmacol Ther 1995; 9: 693-7.
8. Hatlebakk JG, Katz PO, Kuo B, Castell DO,. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998; 12: 1235-40.
9. Pehlivanov ND, Olyaee M, Sarosiek I, McCallum RW,. Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. Aliment Pharmacol Ther 2003; 18: 883-90.
10. Allen L, Poh CH, Gasiorowska A, et al. Increased oesophageal acid exposure at the beginning of the recumbent period is primarily a recumbent-awake phenomenon. Aliment Pharmacol Ther 2010; 32: 787-94.
11. Wagner S, Gladziwa U, Gebel M, Schuler A, Freise J, Schmidt FW,. Circadian pattern of intragastric acidity in duodenal ulcer patients: a study of variations in relation to ulcer activity. Gut 1991; 32: 1104-9.
12. Saitoh T, Watanabe Y, Kubo Y, et al. Intragastric acidity and circadian rhythm. Biomed Pharmacother 2001; 55 (Suppl 1): 138s-41s.
13. Zentilin P, Dulbecco P, Bilardi C, et al. Circadian pattern of intragastric acidity in patients with non-erosive reflux disease (NERD). Aliment Pharmacol Ther 2003; 17: 353-9.
14. Schroeder PL, Filler SJ, Ramirez B, Lazarchik DA, Vaezi MF, Richter JE,. Dental erosion and acid reflux disease. Ann Intern Med 1995; 122: 809-15.
15. Wilder-Smith CH, Wilder-Smith P, Kawakami-Wong H, Voronets J, Osann K, Lussi A,. Quantification of dental erosions in patients with GERD using optical coherence tomography before and after double-blind, randomized treatment with esomeprazole or placebo. Am J Gastroenterol 2009; 104: 2788-95.